PRPO
NASDAQ HealthcarePrecipio, Inc. - Common Stock
Diagnostics & Research
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
๐ Market Data
| Price | $23.68 |
|---|---|
| Volume | 193,226 |
| Market Cap | 42.32M |
| Beta | 1.280 |
| RSI (14-Day) | 55.6 |
| 200-Day MA | $24.15 |
| 50-Day MA | $24.71 |
| 52-Week High | $33.63 |
| 52-Week Low | $13.02 |
| Forward P/E | 60.72 |
| Price / Book | 2.98 |
๐ฏ Investment Strategy Scores
PRPO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (69/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (19/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PRPO in your text
Paste any article, transcript, or post โ the tool will extract PRPO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.